The t(8;21)(q22;q22) occurs frequently in acute myelogenous leukaemia and gives rise to the transcription factor fusion protein, RUNX1-RUNX1T1 (also known as AML1-ETO). To identify the genes dysregulated by the aberrant transcriptional activity of RUNX1-RUNX1T1, we used microarrays to determine the effect of this mutation on gene expression in human progenitor cells and during subsequent development. Gene signatures of these developmental subsets were very dissimilar indicating that effects of RUNX1-RUNX1T1 are highly context dependent. We focused on gene changes associated with the granulocytic lineage and identified a clinically relevant subset of these by comparison with 235 leukaemia patient transcriptional signatures. We confirmed the overexpression of a number of significant genes (Sox4, IL-17BR, CD200 and c-catenin). Further, we show that overexpression of CD200 and c-catenin is also associated with the inv(16) abnormality which like RUNX1-RUNX1T1 disrupts core binding factor activity. We investigated the functional significance of CD200 and c-catenin overexpression in normal human progenitor cells. The effect of IL17 on growth was also assessed. Individually, none of these changes were sufficient to recapitulate the effects of RUNX1-RUNX1T1 on normal development. These data provide the most comprehensive and pertinent assessment of the effect of RUNX1-RUNX1T1 on gene expression and demonstrate the highly context-dependent effects of this fusion gene.
Introduction
One of the most common molecular abnormalities in acute myelogenous leukaemia (AML), observed at a frequency of approximately 12%, is the t(8;21)(q22;q22) translocation. 1 This involves the fusion of RUNX1 (also known as AML1) on chromosome 21 with the RUNX1T1 gene (also known as ETO) on chromosome 8, leading to the formation of the RUNX1-RUNX1T1 fusion protein. 2 Fusions arising from both t(8;21) and inv (16) disrupt the core binding factor function and the transcriptional events regulating haematopoiesis. 3 The importance of these abnormalities in leukaemogenesis is underscored by the fact that each is closely associated with a particular subset of AML; 90% of patients with an t (8;21) are associated with an inhibition in granulocytic differentiation equating with an AML subtype, French-American-British (FAB)-M2 4 while inv (16) patients are predominantly associated with the M4 subtype. 5 Both abnormalities are indicative of good prognosis. 6 In our previous work we showed that RUNX1-RUNX1T1 selectively inhibits the granulocytic and erythroid differentiation capacity of normal human progenitors. 7, 8 It is implicit that RUNX1-RUNX1T1 disturbs the transcriptional processes that regulate haematopoietic development, and indeed it may inhibit transcription of RUNX1 target genes by recruiting complexes consisting of mSin3 and nuclear hormone co-repressors. 9, 10 On the other hand, RUNX1-RUNX1T1 has also been reported to promote gene transcription, for example, AP-1. 11, 12 Previous studies have identified target genes dysregulated by RUNX1-RUNX1T1 in human leukaemia cell lines such as U937 13, 14 or in L-G mouse cells. 15 However, the consequences of RUNX1-RUNX1T1 expression are likely to be critically dependent on the transcriptional environment in which the fusion protein is expressed.
In this report, we determined the effect of RUNX1-RUNX1T1 on gene expression in human haematopoietic progenitors as well as during their subsequent development into granulocytic, monocytic and erythroid cells. To focus on genes relevant to leukaemogenesis, we also performed microarray analysis of 235 AML patients to identify dysregulated genes of clinical significance. Using this strategy we identified molecular differences in human cells that may be responsible for the observed dysregulated development arising from RUNX1-RUNX1T1 as a single abnormality. We identified dysregulation of a number of genes with putative involvement in leukaemogenesis. We additionally performed analyses of a number of these, including g-catenin (also known as plakoglobin or Jup), which plays a role both in cell adhesion and in Wnt signalling. 16 We show that g-catenin is specifically overexpressed in both RUNX1-RUNX1T1 cells and in human t(8;21) disease and inv (16) leukaemias and that unlike RUNX1-RUNX1T1, overexpression of g-catenin in human cells does not inhibit differentiation.
Materials and methods

Cell culture and gene transduction
Human CD34
þ cells (495% pure) were isolated, cultured and transduced as previously described. 8 PINCO-g-catenin was kindly provided by Xiaomin Zheng (Frankfurt, Germany). 17 cDNA for CD200 was kindly provided by I.M.A.G.E consortium cDNA clone I.D. 5299899 18 and subsequently subcloned into the PINCO expression plasmid. Transduced cells were used for Affymetrix microarray analysis and for functional/phenotypic analysis at day 3 (n ¼ 4) and later time points (n ¼ 4). Colony assays were initiated on day 3 by limiting dilution in 96U plates (0.3 cells per well) in liquid medium containing IL-3, SCF, G/GM-CSF at 5 ng ml À1 and IL-17B/E (1, 10 or 100 ng ml
À1
(R&D systems, Abingdon, UK). Cultures were incubated at 371 C with 5% CO 2 . Individual colonies (450 cells) were harvested after 7 days following plating. To calculate the growth of myeloid cells at each time point indicated, a portion of each culture was analysed by flow cytometry (see below) to determine the proportion of CD13 þ CD36 lo cells present in the culture.
RUNX1-RUNX1T1 and control matched transduced cells were also cultured until day 6 and were fractionated into the main progenitor groups for microarray analysis. A depletion strategy using the Miltenyi Biotec MiniMACS system was used for this purpose. Briefly, myeloblasts (CD15 þ ) were enriched from mixed lineage transduced cells by serial depletion of monoblasts (CD14 hi ) and erythroblasts (CD36 þ ) using immunomagnetic beads directed against those antigens. Fractionation efficiency and lineage identities were confirmed using cell surface phenotyping and RNA was extracted as described in Supplementary Methods.
Cell surface phenotype and differentiation analysis
At the time points indicated, liquid cultures were analysed by four-colour immunophenotypic analysis. Cells were stained with CD13-APC (Universal Biologicals Cambridge, UK) in combination with CD15-biotin (Sigma, Poole, Dorset) or CD36-biotin (Ancell, Bayport, MN, USA) and one of the following PElabelled antibodies (Dako, Cambridgeshire, UK): CD11b or CD34; biotinylated CD15 or CD36 were subsequently labelled with Streptavidin-PerCP-Cy5.5 (BD). All reactions were controlled with the appropriate isotype-matched irrelevant antibody. Incubations were performed at 41 C for 30 min in the presence of 0.5% human gamma globulin (Sigma). Reagent concentrations were as recommended by the manufacturer. Flow cytometric data (acquired using a FACSCalibur cytometer, BD Biosciences, Oxford, UK) were analysed using FCS express v3.0 (DeNovo Software, Ontario, Canada). The threshold for GFP positivity was determined from the autofluorescence of GFP negative cells in mock-transduced cultures; for antibody labelled cells, this was determined from control stained cells (in each case, set to 95% of controls). Significance of difference was tested using the Student's t-test or ANOVA. Minitab software version 12.0 (Minitab Inc., Coventry, UK) was used for all analyses.
Patients and control sample materials
A subset of bone marrow samples (n ¼ 235) from patients who had enrolled in the MRC-UK AML clinical trial protocol and were sent to or collected locally and fully processed at UHW Cardiff were used in this study. Sample collection, processing, clinical and biological characteristics of normal healthy donors (n ¼ 9), patients with a t(8;21)(n ¼ 11) and other FAB-M2 patients (that is, without the t(8;21)) (n ¼ 28) are described in Supplementary Table 1 . Following storage in tissue banks, RNA of sufficient quantity and quality were extracted (see Supplementary Methods).
Affymetrix microarray analysis
The Affymetrix data are available as Supplementary material on http://www.ebi.ac.uk/arrayexpress/query/entry (accession number e-mexp-583). MAS software (target intensity) was used to translate the scanned images into expression analysis files. Unique signal values for each gene together with a 'Detection P' value indicating whether a transcript was reliably detected (present), marginally detected (marginal) or not detected (absent) were exported into Genespring v7.3 (Agilent Technologies, Wokingham, UK). Target intensity values from each array were normalised per array (to median) and per gene (to 50th percentile). The resulting expression levels on each chip were normalised around 1, which enabled the comparison of different experiments. Data were filtered to remove all genes that changed by o1.5-fold in RUNX1-RUNX1T1-expressing cells when compared to controls and an additional three-arm approach was applied to identify differentially regulated genes. Statistically significant changing genes were identified using ANOVA (parametric test based on the cross gene error model) ('ACGEM') (Po0.05) or a 'paired t-test' in which RUNX1-RUNX1T1-transduced human progenitor cells were normalised to respective controls and filtered on confidence in Genespring (Po0.05). Where possible the Benjamini-Hochberg multiple testing correction was applied to both these strategies, otherwise the level of significance was reduced to Po0.01. A third nonstatistical 'pairing' approach was applied to changes in gene expression (present or marginal and 41.5-fold differences) in individually paired human progenitor samples. Each of these three analytical approaches was combined in a Venn's diagram to identify biological and statistically significant changing genes by at least two of the three strategies (Figure 2a ).
Protein expression analysis of some gene identified by microarray analysis
To confirm RUNX1-RUNX1T1 protein expression and microarray overexpression of Sox4, IL-17BR and g-catenin in RUNX1-RUNX1T1-transduced cells, we performed western blot analysis. Detection of each protein was determined using a monoclonal or polyclonal antibody in conjunction with an antimouse Amersham ECL Advance Western Blotting Detection Kit (GE Healthcare, Bucks, UK) according to the manufacturer's instruction. Antibodies used include ETO (1:1000, Oncogene, Darmstadt, Germany), g-catenin (1:1000, BD Biosciences), Sox4 (1:50 Abcam, Cambridge, UK) and IL-17BR (1:250 R&D Systems). In the case of CD200, a PE conjugated antibody (BD Biosciences) was used and protein expression was determined by flow cytometry using similar protocols outlined above (see 'Cell surface phenotype and differentiation analysis').
Results
Generation of human progenitor cells expressing RUNX1-RUNX1T1 for microarray analysis
Human CD34
þ haematopoietic cells (which constitute a mixed progenitor population) were retrovirally transduced with a vector co-expressing RUNX1-RUNX1T1 and GFP. Using this approach we generated control (GFP alone) and RUNX1-RUNX1T1 matched CD34 þ cultures (four independent replicate sets) that were used for microarray analysis immediately following retroviral transduction (day 3 of culture). Due to the high frequency of retroviral transduction (B70%), enrichment of transduced cells was unnecessary (Supplementary Figure 1) . The expression of the fusion gene in this context has previously been established. 8, 19 In addition, control and RUNX1-RUNX1T1 matched populations constituting individual lineages (erythrocytic, granulocytic and monocytic) were isolated from day 6 cultures (Figure 1 ). This enabled us to also examine lineagespecific effects of RUNX1-RUNX1T1.
Identification of genes dysregulated by RUNX1-RUNX1T1 in normal human haematopoietic cells
Following total RNA isolation, cDNA synthesis and in vitro transcription, biotinylated cRNA from each sample was hybridised to Affymetrix human 133A oligonucleotide arrays, which allowed the simultaneous analysis of approximately 14 500 genes (represented by 22 283 probe sets) in both individual lineages and also on temporal changes (over days [3] [4] [5] [6] . Supplementary Figure 2 shows an unsupervised hierarchical cluster tree, which demonstrates the reproducibility of individual samples between transduced cultures of different lineage subsets. To identify statistically significant changes in expression, we performed a t-test, ACGEM and a nonstatistical strategy (pairing), which took into account changes in individual pairs of cord blood (see Materials and methods). We analysed dysregulated probe sets that passed at least two of these three criteria (Figure 2a and Supplementary Table 2 ). The most striking feature of these lists (#1-#4) was their dissimilarity with only six probe sets common to all four lists ( Figure 2b ). These genes included CYP1A1, TM4SF1, CRHBP, HSP27 and Sox4 (represented by two probe sets) ( Table 1 ). These data suggest that the effects of RUNX1-RUNX1T1 are highly context dependent. Consistent with a previous study using mouse L-G cells, 20 the majority of gene changes were increases in expression (list #1: 50% up; list #2: 76% up; list #3: 77% up; list #4: 89% up); therefore, though RUNX1-RUNX1T1 may directly repress the Figure 1 Purification of individual lineages expressing RUNX1-RUNX1T1 used in Affymetrix microarray analysis. Representative density plots of RUNX1-RUNX1T1 transduced human progenitor cells enriched for specific lineages on day 6 of culture using a MiniMACS depletion strategy. Quadrants delimit background fluorescence of control-stained/mock-transduced cells. Similar data were generated from control cultures expressing GFP alone (not shown). 21 these data may not support the view that the overall consequence of RUNX1-RUNX1T1 expression is transcriptional repression. A caveat to this is that the presence of low levels of untransduced cells within the AML1-ETO transduced population will to some extent reduce the sensitivity of detection of negatively regulated genes. Further, in day 3 progenitors, we did observe repression (approximately twofold) of a number of developmentally significant transcription factors (CEBPa, GATA-1, PU.1 and RARa) as well as repression of a number of genes associated with erythroid development (NF-E2, EKLF and GATA2). However, none of these changes were sustained in any of the individual lineages, suggesting that these changes were correlative with the developmental disruption provoked by RUNX1-RUNX1T1 8, 19 rather than being causative. We reasoned that we could enrich for RUNX1-RUNX1T1 target genes likely to be causal in mediating developmental dysregulation by looking for gene changes, which were sustained in the granulocyte lineage (which is most closely associated with t(8;21) leukaemias). Using this approach, 26 changes (22 genes) were sustained in the granulocyte-enriched population (Table 1 and Figure 2a , list #5). Each of these coincident changes was co-directional (that is, they were similarly dysregulated on day 6 compared with the day 3 list). Features of this list included strong up regulation of TM4SF1 (L6), which is commonly overexpressed in solid tumours 22 and the inducible cytochrome P450 isozyme, CYP1A1, which is known to be developmentally regulated in haematopoiesis. 23 
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Correlative analysis of gene changes in AML patients
We next established which of the above gene changes were common to leukaemia patients. Using our database of 235 AML patients we identified which of these changes were dysregulated in t(8;21) patients and in other AML subtypes including t(8;21)-negative M2 patients (other M2). A high proportion of the probe sets dysregulated in human progenitor/granulocyte cells were also dysregulated in t(8;21) patients (12/26; 46%) representing 9/22 genes ( Table 1) . These genes were thereby defined by this 
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Leukemia criterion as a potentially clinically relevant subset. This selection excluded probe sets with the largest fold differences in particular, TM4SF1; however, previous reports have also shown this gene not to be overexpressed in t(8;21) patients. 24 In comparison to other AML subsets, two of these (IL-17BR and IL-10R) were exclusive to t(8;21) patients, while only one gene (ALOX5AP) was dysregulated in all subtypes. Of the remainder, a high proportion were also found to be similarly dysregulated in the M0-M2 subtypes and inv(16) patients (Table 1) .
Four of these potentially clinically relevant gene changes (Sox4, IL-17BR, CD200 and g-catenin) have been shown from previous work to be functionally significant in the haematopoietic context. 14, [25] [26] [27] [28] Each was shown to be also overexpressed at the protein level, thereby validating the microarray data (Figure 3) . Further, we overexpressed CD200 or g-catenin in human CD34 þ progenitor cells (Supplementary Figure 1) to determine whether their overexpression influenced the expression of the other clinically relevant proteins (Sox-4, IL-17BR, CD200 or g-catenin). Figure 4 demonstrates that neither CD200 nor g-catenin overexpression modulated expression of these proteins, indicating that the overexpression of these proteins was not inter-dependent. Sox4 is a transcription factor, which has not been previously shown to be overexpressed in AML but has been shown to have the capacity to inhibit granulocytic differentiation in 32D cells. 25 Overexpression of interleukin-17 receptor (IL-17BR) has been previously associated with t(8;21) leukaemias. 26 It has been reported that IL-17 acts as a stimulatory haematopoietic cytokine by expanding myeloid progenitors and initiating granulocyte proliferation. 29 Since the overexpression of its receptor might in part explain the manifestation of RUNX1-RUNX1T1-associated disease in this lineage, we determined whether RUNX1-RUNX1T1-expressing human progenitor cells had an altered response to IL-17. Colony assays were performed in the presence of IL-17B and E alone or in combination (the ligands for the B-type IL-17 receptor). As we have previously shown RUNX1-RUNX1T1-suppressed initial colony forming potential 8 compared with control cells (Supplementary Table 3 ); however, neither IL-17B nor IL-17E nor a combination of both cytokines significantly affected their colony forming potential at any concentration tested (Supplementary  Table 3 ). Further, when RUNX1-RUNX1T1-expressing cells were cultured in the presence of these cytokines (either individually or in combination), there was no change in the growth profile of these cells (Supplementary Figure 3) . These data suggest that while RUNX1-RUNX1T1 may increase the expression of IL17B receptor, this does not apparently correlate with an altered response to known ligands of this receptor.
CD200 is a membrane-associated antigen, which is broadly expressed on many different cell types and appears to have immunosuppressive function. 30 Since its expression is associated with poor prognosis in both multiple myeloma and AML, 28, 31 we examined whether CD200 affected the development of haematopoietic progenitor cells. We overexpressed CD200 in human CD34 þ progenitor cells (Supplementary Figure 1) and followed the development of haematopoietic progenitor cells in bulk liquid culture and in colony assays. Overexpression of CD200 had no significant effect on the myeloid colony forming potential (Supplementary Table 3 ). Further, we observed no changes in proliferation or in the differentiation of cells overexpressing CD200 (data not shown). Taken together, these data suggest that while CD200 is dysregulated by RUNX1-RUNX1T1, it does not recapitulate any of the effects observed with the fusion gene on haematopoietic development. g-Catenin (also known as JUP, plakoglobin) functions both as a major structural protein in the adherens junction complex and as a transcription factor when translocated to the nucleus. 32 It has previously been shown to be upregulated by both RUNX1-RUNX1T1 and PML-RARa in U937 cells.
14 These authors also indicated that this protein was upregulated in AML patients expressing these fusions (using a pooled group of 9 patients compared to 53 patients without these translocations). Using our larger cohort of 235 AML patients, we were able to correlate g-catenin with each AML subtype ( Figure 5 ). We found t(8;21) patients significantly (Po0.01) overexpressed g-catenin by 3.0-fold when compared to FAB-M2 patients without this cytogenetic abnormality. Expression of g-catenin in patients with PMLRARa (M3 subtype) was significantly lower that that observed in t(8;21) patients and otherwise not significantly different from closely related subtypes. One striking observation was that, patients expressing an inv(16) mutation (generally associated with FAB-M4) also significantly overexpressed g-catenin expression by 2.9-fold when compared to M4 individuals without an inv(16) mutation (Po0.0001). This data, therefore, show for the first time that overexpression of g-catenin is particularly associated with leukaemias with mutations affecting core binding factor activity such as t(8;21) and inv (16) , both of which are associated with good prognosis.
Unlike RUNX1-RUNX1T1, overexpression of g-catenin does not inhibit granulocytic development
A defining feature of RUNX1-RUNX1T1 is its ability to promote the self-renewal of human cells and selectively inhibit the differentiation of granulocytic cells, thereby extending their proliferative capacity. 7, 8 It has previously been shown that g-catenin overexpression promotes self-renewal of haematopoietic progenitor cells, 17 an observation we were able to corroborate by limiting dilution/serial replating (data not shown). However, it is not known whether this protein can affect the development of human haematopoietic cells. We, therefore, compared the effect of g-catenin with RUNX1-RUNX1T1 on the development of these cells in bulk liquid culture. Using the same retroviral vector as employed for RUNX1-RUNX1T1 overexpression (Supplementary Figure 1) , we overexpressed g-catenin in human CD34 þ progenitor cells (Figure 6a) . Consistent with our previous observations, RUNX1-RUNX1T1-expressing cells displayed an initial inhibition in growth (threefold reduction on day 6 compared with controls) followed by extended proliferation of differentiation-blocked myeloid cells (Figure 6b ). In contrast, cells overexpressing g-catenin proliferated in a similar manner to control cells. The morphology of these cultures was examined on day 17 of culture ( Figure 6c ). As expected, RUNX1-RUNX1T1-expressing cells displayed an immature myeloid phenotype as previously described. 8 In contrast, cultures overexpressing g-catenin had normal morphology dominated by mature neutrophils. To confirm these data we examined the development of these cultures over 15 days following retroviral transduction by using multiparameter flow cytometry. Normal myeloid development is associated with loss of CD34 expression and upregulation of CD14, CD15 and CD11b. We found that like RUNX1-RUNX1T1, g-catenin overexpression caused significant retention of CD34 expression on myeloid cells (Figure 6d ; left panel) supporting the previous observation that g-catenin overexpression was able to promote self-renewal. 17 However, while RUNX1-RUNX1T1-expressing cells delayed upregulation of markers associated with granulocytic development, CD15 and CD11b (Figure 6d ; middle panels), overexpression of g-catenin showed no delay in the upregulation of these antigens compared with control cells (and was indeed somewhat enhanced at some time points). Neither g-catenin, nor (as previously shown) RUNX1-RUNX1T1, suppressed the expression of the monocytic antigen CD14 (Figure 6d ; right panel). Taken together, these data suggest that unlike RUNX1-RUNX1T1, overexpression of g-catenin does not significantly impair subsequent granulocytic development.
Discussion
Certain fusion proteins, of which RUNX1-RUNX1T1 is an archetypal example, drive the leukaemogenic process to the extent that they give rise to discrete subsets of AML. Previously, we have devised a model based on normal human progenitors, which enabled us to analyse the consequences of RUNX1-RUNX1T1 expression as a single abnormality. These studies have shown that RUNX1-RUNX1T1 is able to inhibit the differentiation of myeloid cells and promote their self-renewal (consistent with its putative initiating role). 8, 19 Using Affymetrix microarray analysis, we have identified the genes dysregulated by RUNX1-RUNX1T1 in normal human progenitors and during subsequent dysregulated development of specific myeloid lineages.
We found that RUNX1-RUNX1T1 induced a large number of gene changes in CD34 progenitor cells as well as in the individual myeloid lineages. The number of probe sets dysregulated in each lineage varied considerably and there was little overlap between these data sets (Figure 2b ). Together 
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A Tonks et al these data indicate that the effect of RUNX1-RUNX1T1 was highly context dependent. This, in turn, probably explains the poor concordance with RUNX1-RUNX1T1 targets identified in other systems (which mostly used cell lines [13] [14] [15] ). Of the RUNX1-RUNX1T1 target genes previously cited in a recent review, 33 only eight (ID2, CD11a, NF-E2, CSF-1, CEBPa, JUND, UBP43 and EAR-2) were dysregulated in any of our RUNX1-RUNX1T1 gene lists (Supplementary Table 2 ) and of these only four (CSF-1, EAR-2, NF-E2 and CEBPa) were dysregulated in t(8;21) patients. As has been previously reported, 34 we observed repression of CEBPa in day 3 progenitors (2.3-fold; see Supplementary Table 2) ; however, repression of CEBPa was not sustained during subsequent development of any lineage and consistent with this, there was also no significant repression of this gene in t(8:21) patient blasts when compared with normals (which are most closely developmentally matched with 
A Tonks et al our day 6 granulocyte preparation). Previously, it has been reported that t(8:21) patients have dramatically reduced levels of CEBPa compared with other types of AML 35 and indeed in our data sets t(8:21) patients did express lower levels than nont(8:21) M2 patients, though the repression was only twofold (as opposed to the sixfold previously reported using RT-PCR based analysis). We compared part of our data set (Figure 2 , gene list #1 and Supplementary Table 2 ) with a previous study by Mulloy et al., 36 which examined the effect of RUNX1-RUNX1T1 on CD34 þ gene expression. Using the same statistical analysis in this present study, we were able to identify seven dysregulated probe sets representing the following five genes CYP1A1, HRH1, FCN1, NPTX1 and CKB. The only genes common to our data were CYP1A1 and NPTX1. However, since Mulloy et al. performed only three replicate analyses, few gene changes were significant. We, therefore, compared all gene changes (41.5-fold) in probe sets common to both GeneChips and found that 43% of gene changes were present in both data sets. Apart from the inclusion of nonstatistical gene changes, some of the discrepancies in the data sets may arise from the fact that the CD34 þ culture/infection protocol performed by Mulloy et al. was more protracted than that employed here and, as we have shown, differentiation strongly influence RUNX1T1-RUNX1T1-induced gene changes. In support of this, we found a greater overlap in our developmentally sustained gene changes (Table 1) with a 75% concurrence rate. Four gene changes were not seen in the data set published by Mulloy et al. (CD200, ALOX5AP, PMP22 and L6), whereas our data only demonstrated a significant upregulation of TrkA in t(8;21) patients. Taking these data as a whole, our conclusion is that gene profiling for RUNX1-RUNX1T1 target genes is only relevant to the context in which it is performed and it is for this reason we have based our study on normal human progenitors cells, which is the most relevant model system available.
This study is the first to employ the U133 GeneChips in this context, which (containing over 22 000 probe sets) inevitably meant that new RUNX1-RUNX1T1 target genes would be identified. Amongst these were a number of functionally significant genes which were also dysregulated in subsequent granulocytic development as well as in t(8;21) patients. Overexpression of both IL-17BR (encoding the receptor for IL-17B and IL-17E 37 ) and the Sox4 transcription factor have been previously associated with myeloid or B-and T-cell leukaemias in BXH2 and AKXD recombinant inbred mice by virtue of the fact they are preferential sites for proviral integration 38 raising the concern that these may have been overexpressed in these data sets by the same mechanism. However, these genes were also overexpressed in t(8;21) patients and it is furthermore highly unlikely that clonal populations overexpressing these genes could have emerged within the 48 h period the cells were exposed to virus. Neither of these genes has been previously identified as a RUNX1-RUNX1T1 target genes, though overexpression of IL17BR has been previously associated with t(8;21) leukaemias. 26 It has been reported that IL-17 acts as a stimulatory haematopoietic cytokine by initiating proliferation of neutrophils (reviewed Schwarzenberger and Kolls
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). The overexpression of its receptor might in part explain the manifestation of RUNX1-RUNX1T1-associated disease in this lineage. However, when human RUNX1-RUNX1T1-expressing CD34 þ progenitor cells were cultured with IL-17 (B or E isoform or in combination), no significant effects on colony growth or bulk culture growth were observed, suggesting an increase in IL-17B receptor expression does not correlate with an increased response to known ligands. Sox4 is one of a family encoding HMG-box transcription factors. It has been shown in 32D cells that overexpressing Sox4 inhibits granulocytic differentiation. 25 Whilst the dysregulation of Sox4 has not been confirmed in human leukaemias, it has, however, been implicated in carcinoma of the colon 39 suggesting that Sox4 may contribute to cancer development.
Another upregulated gene with putative involvement in leukaemogenesis was CD200 (also known as Mox2). Ectopic overexpression of CD200 did not, however, affect haematopoietic progenitor development using the model described here, though this was not surprising given that CD200 has no intrinsic signalling activity. 40 Nevertheless, CD200 confers poor prognosis in noncore-binding factor-associated AMLsFpossibly by provoking immunosuppression and inhibiting immunological clearance of residual disease. From this perspective, it is paradoxical that CD200 should be overexpressed in t(8;21) and inv(16) leukaemias, which are generally associated with good prognosis. It is possible that even within these subgroups the level of CD200 expression may influence survival; however, we currently have insufficient patients within these groups to test this possibility.
Of the nine genes ( Table 1 ) that were determined to be dysregulated by RUNX1-RUNX1T1, only g-catenin had previously been associated with dysregulation in response to RUNX1-RUNX1T1. Further, g-catenin was the only gene containing a RUNX1 consensus binding site (TG(T/C)GGT) in its promoter/enhancer region. g-Catenin is a close homologue of b-catenin, which has been intensively studied because of its important roles in development and epithelial cancer. 41 Each of these catenins appears to function both as a major structural protein in the adherens junction complex and as a transcription factor when translocated to the nucleus. 32 Our observations showed that g-catenin was overexpressed in normal human progenitor cells transduced with RUNX1-RUNX1T1 (B2.4-fold), an observation confirmed at the protein level. This is consistent with previous data based on U937 cells transduced with RUNX1-RUNX1T1. 14 We have extended these studies by identifying overexpression of g-catenin as one of the fundamental gene changes associated with human progenitor granulocytes. In addition, we examined its significance in 235 transcriptional signatures associated with each AML subtype. We have shown for the first time that the highest levels of g-catenin are associated not only with t(8;21) leukaemias but also with another core-binding factor-associated abnormality inv (16) . Interestingly, g-catenin expression is also high in FAB M0 patients. Since approximately 20% of FAB M0 patients have Runx1 mutations, this may account for the high g-catenin expressors in this subgroup. Unfortunately, the Affymetrix microarrays do not discriminate Runx mutations; consequently, we have no immediate way of determining this information. A further consideration is that these Runx mutations appear to have different functional consequences (compared with the 8;21 translocation) in that they appear to act in a strongly dominantnegative manner, which is hard to reconcile with enhanced transcription of g-catenin. Both the t(8;21) and inv (16) groups are associated with a favourable prognosis and it is interesting that g-catenin overexpression is associated with tumour suppression in epithelial cells. 42, 43 Furthermore, underexpression of g-catenin has been associated with poor prognosis. 44 There is also evidence that the very rare autosomal recessive disorder in which functional g-catenin is absent may predispose to MDS and AML. 45 On the other hand, there is evidence that g-catenin may also promote leukaemogenesis by promoting stem cell self-renewal possibly via its role in Wnt signalling. 17, 46 Recent evidence shows that the inv(16) abnormality also promotes the self-renewal of human cells. It is, therefore, likely that g-catenin also contributes to enhanced self-renewing capacity in this context. 3 Despite this obvious similarity with the effects of RUNX1-RUNX1T1, there were also obvious contrasts: g-catenin overexpression did not result in initial growth inhibition or promote extended proliferative capacity. Consistent with this, g-catenin did not inhibit granulocyte differentiation. Taken together, these results suggest that overexpression of g-catenin is able to promote the self-renewal of progenitor cells to some extent, but unlike RUNX1-RUNX1T1, overexpression of g-catenin does not suppress the differentiation of granulocytic cells. It is also interesting to note that overexpression of g-catenin (or CD200) did not modulate the protein expression of the RUNX1-RUNX1T1 target genes Sox-4, IL17R or CD200 (g-catenin) indicating that their overexpression was not inter-dependent.
One potential mechanism by which g-catenin may influence haematopoiesis is through its reported capacity to bind the Tcf family of transcription factors, which regulate the transcription of genes such as c-myc and cyclin D1. 47, 48 Indeed recent studies have linked increased b-catenin transcriptional activity with both AML and with chronic myelogenous leukaemia progression. 49, 50 However, g-catenin differs from b-catenin in that it is reported to be a much less efficient transcriptional activator and may even decrease the affinity of some Tcfs for DNA. 51 It has also been suggested that g-catenin may act as a competitor with b-catenin, implying that the relative levels of these catenins may be important. 52 In the model described here, however, we found no induction of b-catenin and no induction of the Tcf/LEF target genes, c-myc and cyclin D1. Moreover, there was no association with either RUNX1-RUNX1T1 or inv(16) AML patients and c-myc and cyclin D1 induction or indeed b-catenin expression. Currently, therefore we can provide no supporting evidence that induction of either c-myc or cyclin D1 forms part of the mechanism of g-catenin action in this context. We are attempting to identify what the transcriptional targets of gcatenin are in each of these contexts. Given the alternative role of g-catenin in cell adhesion, it is also possible that g-catenin overexpression may promote the capacity of RUNX1-RUNX1T1-expressing cells to occupy the stem cell niche. 53, 54 
